Avonza

Product Overview

Avonza is a fixed-dose combination antiretroviral medication containing Lamivudine (300mg), Tenofovir disoproxil fumarate (300mg), and Efavirenz (400mg) in tablet form. This triple-drug combination therapy is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients weighing ≥40 kg. As part of antiretroviral therapy (ART), Avonza works to inhibit viral replication, decrease HIV viral load, and enhance immune system recovery. It serves as a crucial component of HIV management protocols and should be used in accordance with current treatment guidelines.

Therapeutic Indications

Avonza is prescribed for the management of HIV-1 infection in eligible patients. This combination therapy forms part of a complete HIV treatment strategy aimed at:

• Suppressing viral replication
• Maintaining or restoring immune function
• Reducing HIV-related morbidity and mortality
• Preventing disease progression

Note: Avonza does not cure HIV infection or prevent HIV transmission. Strict adherence to the prescribed regimen is essential for therapeutic success and to minimize the risk of developing drug resistance.

Administration Guidelines

For optimal results:

• Take one tablet daily on an empty stomach (preferably at bedtime)
• Swallow whole with water – do not crush, chew, or break
• Maintain consistent dosing schedule
• If a dose is missed, take as soon as remembered unless close to next dose

Bedtime administration may help mitigate potential neuropsychiatric effects associated with efavirenz component.

Mechanism of Action

Avonza combines three antiretroviral agents with complementary mechanisms:

This multi-target approach effectively suppresses HIV replication at multiple stages.

Dosage Protocol

Standard dosing:

• Adults: One tablet daily
• Pediatrics: For patients ≥40 kg – one tablet daily

Dosage adjustments may be required for:

• Renal impairment
• Hepatic dysfunction
• Concomitant medications

Regular monitoring of renal function, liver enzymes, and viral load is recommended.

Therapeutic Advantages

• Simplified once-daily regimen enhances compliance
• Proven efficacy in treatment-naïve and experienced patients
• Comprehensive viral suppression through multiple mechanisms
• Established safety profile with extensive clinical experience
• Reduces pill burden compared to separate component administration

Adverse Effects

Most common (≥10% incidence):

• Central nervous system: Dizziness, insomnia, abnormal dreams
• Gastrointestinal: Nausea, diarrhea
• Dermatological: Rash
• General: Fatigue

These typically resolve within 2-4 weeks of continued therapy.

Important Safety Information

Boxed Warnings:

• Lactic acidosis/severe hepatomegaly with steatosis
• Exacerbations of hepatitis B
• Neuropsychiatric reactions

Additional precautions:

• Renal monitoring required
• Potential drug interactions (CYP3A4 substrates)
• Contraindicated in pregnancy (first trimester)
• Lipid abnormalities may occur

Storage Conditions

• Store at 20-25°C (68-77°F)
• Protect from moisture and light
• Keep in original packaging
• Secure storage away from children

Medical Disclaimer

The information provided herein is for educational purposes only and does not constitute medical advice. This summary does not include all potential warnings, contraindications, or drug interactions. Healthcare providers should reference full prescribing information. Patients should consult their treating physician for personalized medical advice and before making any treatment decisions. This content supports but does not replace professional medical judgment.